Company: DAWN
Filing Date: 2025-11-13
Form Type: SC TO-C
Source: 0001104659-25-110815
Chunk: 6

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-11-13
Form: SC TO-C
Chunk 6
---
 and Parent in connection with the negotiated terms, including being qualified by confidential disclosures made
for the purposes of allocating contractual risk between the parties thereto. Moreover, some of those representations and warranties were
made as of a specified date, may be subject to a contractual standard of materiality different from those generally applicable to the
Target’s or Parent’s SEC filings or may have been used for purposes of allocating risk among the Target, Merger Sub and Parent
rather than establishing matters as facts. Investors should not rely on the representations and warranties or any description of them
as characterizations of the actual state of facts of the Target, Parent, Merger Sub or any of their respective subsidiaries or affiliates.
Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Merger Agreement,
and this subsequent information may or may not be fully reflected in public disclosures by the Target or Parent.

Tender and Support Agreements

On November 12, 2025, in connection with the execution and delivery of the Merger Agreement, the Target’s current directors and executive officers,Bain Capital Life Sciences Fund II, L.P., BCIP Life Sciences Associates, LP and BCLS II Investco, LP (collectively, the “Support
Stockholders”), solely in their respective capacities as stockholders of the Target, each entered into a tender and support agreement
(collectively, the “Tender and Support Agreements”) with Parent and Merger Sub, pursuant to which each Support Stockholder
agreed, among other things, (i) to tender all of the Target Shares held by such Support Stockholder in the Offer, subject to certain exceptions
(including the valid termination of the Merger Agreement), (ii) to, if applicable, vote all of such Support Stockholder’s Target
Shares in favor of the Merger, and (iii) to certain other restrictions on its ability to take actions with respect to the Target and its
Target Shares. The Support Stockholders own approximately 8.5% of the outstanding Target Shares as of November 10, 2025. The Tender and
Support Agreements will terminate upon the earliest of (i) the date and time upon which the Merger Agreement is validly terminated in
accordance with its terms, and (ii) the date and time upon which the Merger becomes effective.

The foregoing description of the Tender and Support Agreements does
not purport to be complete and is qualified in all respects by reference to the full text